Evidence map›Paper›PMID 25455467›Full record

ArticleThe Journal of thoracic and cardiovascular surgery2015

High-molecular-weight polyethylene glycol inhibits myocardial ischemia-reperfusion injury in vivo.

Xianyao Xu, Jennifer L Philip, Md Abdur Razzaque, James W Lloyd, Charlie M Muller, Shahab A Akhter

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of thoracic and cardiovascular surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Institut Georges Lopez-2M as a Novel Lung Preservation Solution Attenuates Ischemia-Reperfusion Injury in a RatTransplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. PEG35 as a Preconditioning Agent against Hypoxia/Reoxygenation Injury.International journal of molecular sciences · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xianyao XuDivision of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Jennifer L PhilipDivision of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Md Abdur RazzaqueDivision of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
James W LloydUniversity of Chicago Pritzker School of Medicine, Chicago, Ill.
Charlie M MullerUniversity of Chicago Pritzker School of Medicine, Chicago, Ill.
Shahab A AkhterDivision of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis. Electronic address: akhter@surgery.wisc.edu.
University of Wisconsin–Madison · USUniversity of Chicago · US

Funding

Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Inhibition of GRK2 to Prevent Ventricular Remodeling and Heart Failure After CABGR01HL107949 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI AKHTER, SHAHAB A · 2011 to 2015
$1.9M
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR000430NHLBI NIH HHS HL107949NHLBI NIH HHS R01 HL107949
6 · The paper itself

Abstract

objectivesCardiac ischemia-reperfusion (I-R) injury remains a significant problem as there are no therapies available to minimize the cell death that can lead to impaired function and heart failure. We have shown that high-molecular-weight polyethylene glycol (PEG) (15-20 kD) can protect cardiac myocytes in vitro from hypoxia-reoxygenation injury. In this study, we investigated the potential protective effects of PEG in vivo.

methodsAdult rats underwent left anterior descending artery occlusion for 60 minutes followed by 48 hours or 4 weeks of reperfusion. One milliliter of 10% PEG solution or phosphate-buffered saline (PBS) control (n = 10 per group) was administered intravenously (IV) immediately before reperfusion.

resultsFluorescein-labeled PEG was robustly visualized in the myocardium 1 hour after IV delivery. The PEG group had significant recovery of left ventricular ejection fraction at 4 weeks versus a 25% decline in the PBS group (P < .01). There was 50% less LV fibrosis in the PEG group versus PBS with smaller peri-infarct and remote territory fibrosis (P < .01). Cell survival signaling was upregulated in the PEG group with increased Akt (3-fold, P < .01) and ERK (4-fold, P < .05) phosphorylation compared to PBS controls at 48 hours. PEG also inhibited apoptosis as measured by TUNEL-positive nuclei (56% decrease, P < .02) and caspase 3 activity (55% decrease, P < .05).

conclusionsHigh-molecular-weight PEG appears to have a significant protective effect from I-R injury in the heart when administered IV immediately before reperfusion. This may have important clinical translation in the setting of acute coronary revascularization and myocardial protection in cardiac surgery.

Indexed as

AnimalsApoptosisCaspase 3Cell SurvivalGlycogen Synthase Kinase 3In Situ Nick-End LabelingMaleMAP Kinase Signaling SystemMolecular WeightMyocardial Reperfusion InjuryPhosphorylationPolyethylene GlycolsProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyCaspase 3Glycogen Synthase Kinase 3Polyethylene GlycolsProto-Oncogene Proteins c-akt

Identifiers

PMID25455467
PMCPMC4459731
OpenAlexW2002872132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.